Vacunación frente al virus de la hepatitis B: respuesta inmune en pacientes con enfermedad renal crónica

Otero, Librado Carrasco; García, C. Hernán; García, I. Andrés; Espinilla, V. Fernández; Dominguez, Stéphanie; Sanz, Julia

doi:10.1016/j.vacun.2019.08.040

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On another note, this study demonstrates that vaccine efficacy is higher in younger patients, with decreased immunity development in patients older than 50 years. These results are in line with other previous research works on the general efficacy of vaccines [ 27 ] and point to a better capacity and higher activity of the immunological system in younger people in the detection of potentially noxious pathogens as the main reason for this. Thus, the immunological response of the organism decreases with age, which in turn causes a lower immunological reaction against vaccines.…”

Section: Discussionsupporting

confidence: 92%

Fendrix® Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B® Vaccination

et al. 2021

View full text Add to dashboard Cite

Hepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with Engerix B® lowers this risk by providing workers with immunity to the virus. However, through the years, we have encountered nonresponsive health personnel to the Engerix B® vaccine; hence, the Occupational Health Service of Poniente Hospital studied the Fendrix® adjuvanted vaccine as an alternative vaccine to develop immunological responses in healthcare workers who do not respond to vaccination with Engerix B®. In our study, we employed a vaccination schedule with the Fendrix® vaccine, performing serology tests on the cases after the application of each dose. The results obtained showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after the first doses. These encouraging results support the future inclusion of this vaccine as one possible alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B®.

show abstract

Section: Discussionsupporting

confidence: 92%